Type 2 diabetes happens when the body cannot properly control blood sugar. Over time, high blood sugar can damage the heart, kidneys, nerves, and eyes. Many treatments are available, including a group of medications called GLP-1 receptor agonists. These drugs help the body release insulin, lower blood sugar, and often support weight loss.
But not everyone responds to GLP-1 medications the same way. A new study published in Genome Medicine explored why. Researchers found that certain genetic differences may influence natural GLP-1 hormone levels and how well GLP-1 medications work.
What Is GLP-1 and Why Does It Matter?
GLP-1 stands for glucagon-like peptide-1. It is a hormone made in the gut after we eat. GLP-1 helps:
- Stimulate insulin release
- Lower blood sugar
- Slow stomach emptying
- Reduce appetite
GLP-1 receptor agonists are medications that copy the action of this hormone. They are commonly used to treat type 2 diabetes and obesity.
However, the study suggests that genetics may affect how much natural GLP-1 a person produces and how well GLP-1 medications work.
The Role of the PAM Gene
The research focused on a gene called peptidyl-glycine alpha-amidating monooxygenase (PAM). This gene helps process certain hormones in the body, including GLP-1.
Inside the body, GLP-1 must go through a chemical process called amidation. Amidation helps stabilize hormones and allows them to function properly. The PAM enzyme is responsible for this process.
The study looked at specific genetic variants, also called risk alleles, in the PAM gene. A risk allele is a version of a gene that increases the likelihood of developing a disease.
Researchers found that people who carry certain PAM risk alleles:
- Had lower levels of active GLP-1
- Showed altered GLP-1 hormone processing
- Had differences in how they responded to GLP-1 receptor agonist therapy
This suggests that the PAM gene plays an important role in both natural GLP-1 production and medication response.
How the Research was Conducted
The researchers examined genetic data from people with and without type 2 diabetes. They measured GLP-1 hormone levels after meals and analyzed how genetic differences affected these levels.
They also studied how individuals with these genetic variants responded to GLP-1 receptor agonist treatment.
The findings showed that carriers of certain PAM variants had impaired GLP-1 hormone activity. In addition, their response to GLP-1 medications appeared to differ compared to non-carriers.
This means that genetics may partially explain why some people respond better than others to the same diabetes medication.
What This Means for Diabetes Treatment
This study highlights the growing importance of personalized medicine. Personalized medicine means tailoring treatment based on a person’s genetic makeup.
If certain genetic variants reduce natural GLP-1 activity, patients may benefit differently from GLP-1 medications. In the future, genetic testing could help doctors decide:
- Which patients are likely to respond best to GLP-1 therapy
- Who may need higher or alternative treatment strategies
- How to better manage diabetes risk
The research does not suggest that GLP-1 medications are ineffective. Instead, it shows that genetics may influence how strongly someone responds.
Why This Research Is Important
Type 2 diabetes is a complex disease influenced by lifestyle, environment, and genetics. Identifying how specific genes affect hormone function gives researchers a clearer understanding of the disease.
The study shows that changes in the PAM gene may increase diabetes risk by altering GLP-1 processing. This connects genetic risk directly to a known biological pathway.
Understanding this pathway could lead to:
- Better prediction of diabetes risk
- More precise medication choices
- New treatment targets in the future
While more research is needed, this study moves us closer to more individualized diabetes care.
The Bottom Line
GLP-1 is a key hormone in blood sugar control. This research shows that certain genetic changes in the PAM gene can affect natural GLP-1 levels and response to GLP-1 medications.
In the future, genetic testing may help doctors better match patients with the right diabetes treatment. Personalized medicine is becoming more realistic, and studies like this are helping guide the way.
Source
Xie L, et al. Type 2 diabetes risk alleles in peptidyl-glycine alpha-amidating monooxygenase influence GLP-1 levels and response to GLP-1 receptor agonists. Genome Med. 2026;18:XX. Available from: https://link.springer.com/article/10.1186/s13073-026-01630-0
